EGFR and neoplasm: One patient with EGFR amplification experienced a persistent partial response to cetuximab in the third‐line setting,10 while another UrC patient with immunohistochemically proven EGFR overexpression experienced a transient 55% decrease in tumour size with gefitinib treatment.14